BMRN Q3 2019 Earnings — BioMarin Pharmaceutical Inc. Revenue & Financial Results | Market Cap Arena

BMRNBioMarin Pharmaceutical Inc.

$12B

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$461M+17.7% YoY

Gross Profit

$364M79.0% margin

Operating Income

$4M0.9% margin

Net Income

$55M11.9% margin

EPS (Diluted)

$0.30

QoQ Revenue Growth

+18.9%

Cash Flow

Operating Cash Flow

$70M

Free Cash Flow

$35M

Stock-Based Comp.

$39M

Balance Sheet

Total Assets

$4.6B

Total Liabilities

$1.5B

Stockholders' Equity

$3.1B

Cash & Equivalents

$423M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$461M	$392M	+17.7%
Gross Profit	$364M	$313M	+16.4%
Operating Income	$4M	-$16M	+125.5%
Net Income	$55M	-$13M	+536.1%

Revenue Segments

Product

$451M50%

Product Four

$163M18%

Product Three

$121M13%

Product Two

$94M10%

Product Seven

$24M3%

Product One

$23M3%

Product Six

$20M2%

Product Five

$6M1%

Geographic Segments

UNITED STATES

$202M44%

Europe

$125M27%

Latin America

$84M18%

Rest Of World

$50M11%